Skip to content
NYSE · WHOLESALE-DRUGS, PROPRIETARIES & DRUGGISTS' SUNDRIES · MID CAP

NU Skin Enterprises, Inc. NUS

18 fiscal years on record · USD · FY2025 reported · SEC filings only
5 YEARS OF DIVIDEND GROWTH
$1.5B
▼ 14.3% YoY
$160.2M
$46.0M
▼ 34.4% YoY

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Nu Skin Enterprises, Inc. develops and distributes a comprehensive line of premium-quality beauty and wellness solutions in nearly 50 markets worldwide. It operates in the direct selling channel, primarily utilizing person-to-person marketing to promote and sell its products, including through the use of social and digital platforms. In 2025, it generated approximately 26% of its revenue from the United States, consisting of its Nu Skin United States and Rhyz businesses, and the remainder from its international markets. As of December 31, 2025, it had approximately 2,800 full- and part-time employees worldwide. Separately, its Mainland China operations employed approximately 5,800 sales employees, not included in that total. It has two primary product categories: beauty products and wellness products. The beauty category is developed and distributed under the Nu Skin and Nutricentials brands, while the wellness category is developed and distributed under the Pharmanex and Beauty Focus brands, among others.

Written from the business description in NU SKIN ENTERPRISES, INC.'s annual report to the U.S. Securities and Exchange Commission, filed 13 February 2026. Every sentence was checked against that document before publication.

Growth

USD 1.5B
Revenue, FY2025 · full 18-year series below
Revenue $B Net income $B
FY2025 · Revenue 1.5 · Net income 0.2
2B3B
2008201120142017202020232025
Compound annual growth
−12.6%
−10.5%
−4.1%
−0.2%
+15.2%
−3.5%
+1.9%
+1.1%
+15.4%
−2.6%
+3.5%
+2.8%
+20.5%
+22.9%
−39.9%
−32.2%
−18.5%
−5.0%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −10.5% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

11 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 4.4% · Net 10.8%
5%10%15%-5%
200820162025
ROE
FY2025 · ROE 22.0%
20%40%-5%-10%-15%
200820162025
Three returns, three denominators.

Each USD of equity produced 22 cents of profit this year.

Cash & shareholders

USD 31.9M
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 46.0
150M300M-100M-200M
200820162025
Net buybacks $M Dividends $M
FY2025 · Dividends 11.8 · Net buybacks 20.0
150M300MDividendsNet buybacks
2008201120142017202020232025

USD 11.8M in dividends and USD 20.0M in buybacks — 20% of the year's profit went back to shareholders.

Total assetsUSD 1.4B
EquityUSD 805.2M
CashUSD 238.6M
Gross debtUSD 224.2M
Net debtUSD -14.4M
Current ratio2.08×

The company holds more cash than debt.

The 18-year record

18 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative—not applicable◌not available in our data
NUS, 18-year financial record
Metric 202520242023202220212020201920182017201620152014201320122011201020092008
Revenue $B1.51.72.02.22.72.62.42.72.32.22.22.63.22.11.71.51.3◌
Operating income $B0.1−0.20.00.10.20.30.30.20.30.20.20.40.60.30.20.20.10.1
EBITDA $B0.1−0.10.10.20.30.30.30.30.30.30.30.40.60.40.30.20.20.2
Income tax $B0.0−0.00.0−0.00.10.10.10.10.10.10.10.10.20.10.10.10.10.0
Net income $B0.2−0.10.00.10.10.20.20.10.10.10.10.20.40.20.20.10.10.1
Free cash flow $B0.00.10.10.00.10.30.10.10.20.20.3−0.20.30.20.20.10.10.1
EPS, diluted $3.18−2.950.172.072.863.633.102.162.362.552.253.115.943.522.382.111.401.02
Dividend / sh $◌◌◌◌◌◌◌◌◌◌0.350.340.300.200.160.12◌◌
Payout %7−8903745241476659556143192224233243
ROE %22.0−19.91.011.616.321.620.916.418.919.215.021.050.438.129.332.126.020.7

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

Compare

This company against its peers

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 87 reconciliationsAUDITED

Reconciled in 18 of the 18 fiscal years we could check. Four checks were skipped: the balance sheet is not tagged before 2009. Two checks were skipped: revenue is not tagged before 2009. One check was skipped: EPS is not tagged before 2008.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityWholesale-Drugs, Proprietaries & Druggists' Sundries
Listed onNYSE
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2008

Share this section

Download image